Lunasin earns new research patent
Australian patent recognises the discovery of lunasin's unique role in promoting cardiovascular health
Reliv International, Inc., a maker of nutritional supplements that promote optimal health, has announced that the Commonwealth of Australia Patents Office has issued a Certificate of Patent to Dr Alfredo Galvez, Chief Scientific Officer at SL Technology, Inc., a Reliv company.
The patent protects Galvez's discovery establishing the lunasin peptide as the component of soy protein that improves specific blood markers associated with cardiovascular health.
'This patent is the latest recognition of the cutting-edge research being conducted by Dr Galvez and his team,' said Dr Carl W. Hastings, Reliv Vice Chairman and Chief Scientific Officer.'
'Lunasin is a remarkable ingredient, and Reliv's exclusive LunaRich products deliver more bioactive lunasin than any other source available today. We're excited about the patent and even more excited about what continued research and product development will mean for Reliv distributors and consumers,' he added.
Galvez has been awarded similar patents in the United States and China. Patent applications are also pending in eight other international markets. Galvez currently holds eight patents surrounding his research related to the lunasin peptide.
